M
Mathieu Bourdenx
Researcher at Albert Einstein College of Medicine
Publications - 45
Citations - 2549
Mathieu Bourdenx is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Neurodegeneration & Autophagy. The author has an hindex of 17, co-authored 38 publications receiving 1661 citations. Previous affiliations of Mathieu Bourdenx include University of Bordeaux & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay,Mathieu Bourdenx,Philippe Gorry,Serge Przedborski,Miquel Vila,Miquel Vila,Stéphane Hunot,Andrew B. Singleton,C. Warren Olanow,Kalpana M Merchant,Erwan Bezard,Gregory A. Petsko,Wassilios G. Meissner +12 more
TL;DR: This work critically assess the potential of experimental therapies targeting α-synuclein, and discusses steps that need to be taken for target validation and drug development.
Journal ArticleDOI
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
Matthieu F. Bastide,Wassilios G. Meissner,Barbara Picconi,Stefania Fasano,Pierre-Olivier Fernagut,Michael Feyder,Veronica Francardo,Cristina Alcacer,Yunmin Ding,Riccardo Brambilla,Gilberto Fisone,A. Jon Stoessl,Mathieu Bourdenx,Michel Engeln,Sylvia Navailles,Philippe De Deurwaerdère,Wai Kin D. Ko,Nicola Simola,Micaela Morelli,Laurent Groc,Maria Cruz Rodriguez,Eugenia V. Gurevich,Maryka Quik,Michele Morari,Manuela Mellone,Fabrizio Gardoni,Elisabetta Tronci,Dominique Guehl,François Tison,Alan R. Crossman,Un Jung Kang,Kathy Steece-Collier,Susan H. Fox,Manolo Carta,M. Angela Cenci,Erwan Bezard +35 more
TL;DR: The present review attempts to provide an overview of the current understanding of dyskinesia and other L-dopa-induced dysfunctions to help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.
Journal ArticleDOI
Selective autophagy as a potential therapeutic target for neurodegenerative disorders.
TL;DR: A change of strategy in the modulation of autophagy might hold promise for future disease-modifying therapies for patients with neurodegenerative disorders.
Journal ArticleDOI
Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.
Mathieu Bourdenx,Jonathan Daniel,Emilie Genin,Federico N. Soria,Mireille Blanchard-Desce,Erwan Bezard,Benjamin Dehay +6 more
TL;DR: It is demonstrated that poly(DL-lactide-co-glycolide) (PLGA) acidic nanoparticles (aNP) restore impaired lysosomal function in a series of toxin and genetic cellular models of PD, i.e. ATP13A2-mutant or depleted cells or glucocerebrosidase (GBA)-mutant cells, as well as in a genetic model of lysOSomal-related myopathy.
Journal ArticleDOI
Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Mathieu Bourdenx,Nikolaos Stavros Koulakiotis,Despina Sanoudou,Erwan Bezard,Erwan Bezard,Benjamin Dehay,Benjamin Dehay,Anthony Tsarbopoulos,Anthony Tsarbopoulos +8 more
TL;DR: The putative direct link between β-amyloid peptide and tau in causing toxicity in Alzheimer's disease as well as α-synuclein in Parkinson's disease is presented, along with some of the most promising therapeutic strategies currently in development for those incurable neurodegenerative disorders.